ArticleFrontiers in bioengineering and biotechnology2026
Advancing
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic syndrome is a pathological state, frequently associated with type 2 diabetes, which is marked by abdominal obesity, impaired insulin action, hypertension, and vascular wall changes. Similar to humans, horses can suffer from equine metabolic syndrome. A representative Methods: In this study, scaffolds manufactured via digital light processing (DLP) exploiting an acrylate-endcapped urethane-based polymer precursor with a polyethylene glycol backbone (AUP2PEG) were coated with collagen or gelatin derivatives. Their cell-interactive properties were evaluated using equine mesenchymal stromal cells (MSC) and endothelial cells (EC). Coating was performed using either UV-induced photopolymerization of gelatin methacryloyl (GelMA) on the surface of the DLP-printed scaffold or physisorption of type I atelocollagen. Results: The GelMA coating formed a thin, uniform layer on the scaffold surface and improved the cytocompatibility of DLP-printed AUP2PEG-based scaffolds for EC and MSC. Furthermore, they permitted MSC trilineage differentiation. To mimic the endothelial damage occurring in metabolic syndrome conditions, the GelMA-coated AUP2PEG scaffolds were incubated in high glucose culture conditions. Short-term cell culture in these conditions significantly reduced the number of viable EC. In contrast, the short-term culture of MSC in these conditions did not result in a similarly deleterious impact on cell viability. Conclusion: In conclusion, GelMA-coated DLP-printed AUP2PEG scaffolds facilitate the growth of EC and MSC. Furthermore, exposing EC cultured on the developed scaffolds to hyperglycemic culture conditions negatively affects the viability of EC, comparable to what is observed in two-dimensional culture conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.